Delivery systems for DNA-binding drugs as gene expression modulators.
Despite the large number of publications describing the synthesis and physicocharacterization of the binding between drugs and DNA, relatively few examine drug delivery systems (DDSs) for these molecules. The aim to find DDSs for DNA-binding drugs (DBDs) was prompted mainly to reduce the toxicity and/or enhance the tumor specificity of systemically administered drugs. With this in mind, we have reviewed the biological effects of some DBDs that are currently used as antitumor drugs and describe a brief selection of DDSs currently in clinical trials or on the market.
Cortesi
R
R
Dipartimento di Scienze Farmaceutiche, via Fossato di Mortara 19, 44100, Tel.: +39 0532 291259; fax: +39 0532 291296, Ferrara, Italy
Nastruzzi
C
C